Sangamo Posts $138.5M Cash After $161M Asset Sales in September MOR
SGMOQ has more than doubled off its 52-week low of $0.01.
Summary
Sangamo's September bankruptcy report shows $138.5M of cash after closing $161M of asset sales, a $143.8M monthly profit, and headcount down to 13 — but the company remains in Chapter 11 with delisted, highly speculative stock.
Key Events · Legal and Risk Events · SGMOQ
-
September MOR Shows $161M Sale Proceeds
The September monthly operating report discloses $161.0M in cash sale proceeds from the Merope and Fabry transactions, with $32.2M of related payments for $128.8M net proceeds.
-
Cash Climbs to $138.5M
Month-end cash rose to $138.5M from $23.2M at August 31, 2026, and the month produced a $143.8M net profit on $161.1M of gross income.
-
Headcount Cut to 13 Employees
Full-time employees fell to 13 from 74 at the petition date as the asset sales closed and operations wound down.
-
Amended July and August MORs Filed
The amendments add disclosure of payments inadvertently made to Rothwell, Figg and Daijogo & Pedersen before their retention as ordinary course professionals.
Analysis · SGMOQ · Life Sciences
The September monthly operating report is the first hard look at Sangamo's balance sheet after the asset sales closed. Cash jumped to $138.5M from $23.2M a month earlier on $161.0M of gross sale proceeds, and the company booked a $143.8M net profit for the month. That cash is what stands between the estate and a liquidation with nothing for equity, but it does not change the core fact: the company is in Chapter 11, has cut staff to 13 people, and its stock trades on the OTC Expert Market with the company itself warning that trading prices may bear little relationship to any recovery for shareholders. The amended July and August reports are minor corrections adding disclosure of payments made to two law firms before they were formally retained.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 31.1% of the 1661 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGMOQ was trading at $0.12 on OTC in the Life Sciences sector, with a market capitalization of approximately $48.9M. The 52-week trading range was $0.01 to $0.67. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.